教室紹介

2013年業績集

受賞

  1. 平成25年度東京医科歯科大学医学研究奨励賞

    松岡　陽

  2. 欧州泌尿器科学会ベストポスター賞

    Fukushima H, Saito K, Ishioka J, Matsuoka Y, Numao N, Koga F, Masuda H, Fujii Y, Sakai Y, Arisawa C, Okuno T, Yonese J, Kamata S, Nagahama K, Akira, Noro, Morimoto S, Tsujii T, Kitahara S, Gotoh S, Higasi Y, Kihara K. Equivalent survival after distal ureterectomy compared to nephroureterectomy in patients with urothelial carcinoma of the distal ureter: A propensity score-matched multi-center study. "Best Poster Presentation" The 28th Annual Congress of the European Association of Urology, Milan, Italy, 2013/3/16

  3. 第101回日本泌尿器科学会総会 総会賞

    藤井靖久，小林秀一郎，古賀文隆，横山みなと，吉田宗一郎，石岡淳一郎，松岡陽，沼尾昇，齋藤一隆，増田均，木原和徳. 膀胱頸部腫瘍は筋層非浸潤性膀胱癌の進展の予測因子である：前向きコホートでの検証と進展予測モデルの作成. 第101回日本泌尿器科学会総会 2013年4月25日

学会発表

欧州泌尿器科学会（European Association of Urology annual congress）

  1. Kihara K, Takeshita H, Masuda H, Koga F, Saito K, Matsuoka Y, Numao N, Fujii Y. Novel three-dimensional head-mounted display system (RoboSurgeon System) : application to initial 60 cases of gasless single-port access urologic surgeries. The 28th Annual Congress of the European Association of Urology, Milan, Italy, 2013/3/17

  2. Kihara K, Fujii Y, Masuda H, Saito K, Koga F, Numao N, Matsuoka Y. New 3-dimensional head-mounted display system (RoboSurgeon system) applied to gasless, single-port access adrenalectomy. The 28th Annual Congress of the European Association of Urology, Milan, Italy, 2013/3/17

  3. Kihara K, Fujii Y, Masuda H, Saito K, Koga F, Numao N, Matsuoka Y. New 3-dimensional head-mounted display system (RoboSurgeon system) applied to gasless, single-port access, clampless partial nephrectomy. The 28th Annual Congress of the European Association of Urology, Milan, Italy, 2013/3/17

  4. Yoshida S, Kobayashi S, Koga F, Ishioka J, Ishii C, Tanaka H, Nakanishi Y, Matsuoka Y, Numao N, Saito K, Masuda H, Fujii Y, Kihara K. The ADC value is a prognostic biomarker of upper urinary tract cancer: Potential application to preoperative risk stratification. The 28th Annual Congress of the European Association of Urology, Milan, Italy, 2013/3/16

  5. Fukushima H, Saito K, Ishioka J, Matsuoka Y, Numao N, Koga F, Masuda H, Fujii Y, Sakai Y, Arisawa C, Okuno T, Yonese J, Kamata S, Nagahama K, Akira Noro, Morimoto S, Tsujii T, Kitahara S, Gotoh S, Higasi Y, Kihara K. Equivalent survival after distal ureterectomy compared to nephroureterectomy in patients with urothelial carcinoma of the distal ureter: A propensity score-matched multi-center study. The 28th Annual Congress of the European Association of Urology, Milan, Italy, 2013/3/16

  6. Matsuoka Y, Ishioka J, Numao N, Tanaka H, Yoshida S, Yokoyama M, Koga F, Saito K, Masuda H, Fujii Y, Kihara K. Simple prediction model of side-specific extracapsular extension based on percent positive biopsy cores and tumor contact length with the capsule on MRI. The 28th Annual Congress of the European Association of Urology, Milan, Italy, 2013/3/17

  7. Matsuoka Y, Numao N, Saito K, Tanaka H, Yoshida S, Yokoyama M, Ishioka J, Koga F, Masuda H, Fujii Y, Kihara K. Candidate selection for quadrant-ablation focal therapy of prostate cancer through a combination of extended 14-core biopsy and MRI. The 28th Annual Congress of the European Association of Urology, Milan, Italy, 2013/3/17

  8. Fujii Y., Kobayashi S., Koga F., Yokoyama M., Yoshida S., Ishioka J., Matsuoka Y., Numao N., Saito K., Masuda H., Kihara K. Prediction of progression in patients with non-muscle invasive bladder cancer based on histologic grade, T stage, recurrence rate and bladder neck involvement: the BN-GTR model. The 28th Annual Congress of the European Association of Urology, Milan, Italy, 2013/3/17

  9. Koga F, Fujii Y, Ishioka J, Matsuoka Y, Numao N, Saito K, Masuda H, Kawakami S, Kihara K. Risk factors for intravesical tumor recurrence in muscle-invasive bladder cancer patients treated with selective bladder-sparing approaches. The 28th Annual Congress of the European Association of Urology, Milan, Italy, 2013/3/17

  10. Saito K, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Koga F, Masuda H, Fujii Y, Hayashi K, Shibuya H, Kihara K. Focal therapy for prostate cancer using I125seed implantation: Hemiablative brachytherapy for patients selected using extended biopsy and MRI. The 28th Annual Congress of the European Association of Urology, Milan, Italy, 2013/3/17

  11. Ishioka J, Saito K, Matsuoka Y, Numao N, Koga F, Masuda H, Fujii Y, Sakai Y, Okuno T, Arisawa C, Kamata S, Nagahama K, Yonese J, Noro A, Tsujii T, Morimoto S, Higashi Y, Fukui I, Kihara K. Risk stratification model for predicting bladder recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma. The 28th Annual Congress of the European Association of Urology, Milan, Italy, 2013/3/17

  12. Kijima T, Koga F, Fujii Y, Yoshida S, Tatokoro M, Kihara K. Zoledronic acid sensitizes renal cell carcinoma cells to radiation by downregulating STAT1. The 28th Annual Congress of the European Association of Urology, Milan, Italy, 2013/3/17

米国泌尿器科学会（annual meeting of the American Urological Association）

  1. Kihara K, Takeshita H, Masuda H, Koga F, Saito K, Matsuoka Y, Numao N, Fujii Y. Novel three-dimensional head-mounted display system (RoboSurgeon System) : application to the initial 80 cases of gasless single-port access urologic surgeries. The 107th annual meeting of the American Urological Association, San Diego, USA, 2013/5/6

  2. Yachida Y, Takeshita H, Sawamura C, Tanaka H, Sato S, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Fujii Y, Kihara K. Bone abnormal signal incidentally found in pre-biopsy diffusion-weighted MRI for suspicious of prostate cancer; what does the signal reflect? The 107th annual meeting of the American Urological Association, San Diego, USA, 2013/5/8

  3. Matsuoka Y, Ishioka J, Numao N, Tanaka H, Yoshida S, Yokoyama M, Koga F, Saito K, Masuda H, Fujii Y, Kihara K. Impact of MRI on the prediction of side-specific extracapsular extension: Nomogram based on tumor contact length and percent positive biopsy cores. The 107th annual meeting of the American Urological Association, San Diego, USA, 2013/5/5

  4. Matsuoka Y, Numao N, Saito K, Tanaka H, Yoshida S, Yokoyama M, Ishioka J, Koga F, Masuda H, Fujii Y, Kihara K. Combination of extended biopsy and MRI identifies candidates for quadrant-ablation focal therapy of prostate cancer. The 107th annual meeting of the American Urological Association, San Diego, USA, 2013/5/6

  5. Fujii Y, Yamamoto S, Yonese J, Masuda H, Urakami S, Kitsukawa S, Kihara K, Fukui I. Long-term results of the processus vaginalis transection method to prevent postradical prostatectomy inguinal hernia. The 107th annual meeting of the American Urological Association, San Diego, USA, 2013/5/6

  6. Numao N, Magnetic resonance imaging guided prostate biopsy versus systematic 14-core prostate biopsy including anterior samplings in detecting significant cancer and assessing cancer aggressiveness. The 107th annual meeting of the American Urological Association, San Diego, USA, 2013/5/6

  7. Numao N, Potential of prebiopsy multiparametric magnetic resonance imaging to reduce initial biopsies in men with suspected clinically localized prostate cancer. The 107th annual meeting of the American Urological Association, San Diego, USA, 2013/5/6

  8. Nakanishi Y, Komai Y, Masuda H, Matsuoka Y, Numao N, Yoshimoto T, Saito K, Koga F, Fujii Y, Ogawa Y, Kihara K The abnormality of glucose tolerance test in pheochromocytoma: one of the significant findings of postoperative hypoglycemia. The 107th annual meeting of the American Urological Association, San Diego, USA, 2013/5/6

  9. Koga F, Kobayashi S, Fujii Y, Yokoyama M, Nakanishi Y, Ishioka J, Matsuoka Y, Numao N, Saito K, Masuda H, Kihara K. Prognostic significance of positive urine cytology in non-muscle invasive bladder cancer patients. The 107th annual meeting of the American Urological Association, San Diego, USA, 2013/5/6

  10. Koga F, Fujii Y, Ishioka J, Matsuoka Y, Numao N, Saito K, Masuda H, Kawakami S, Kihara K. Predictors of intravesical tumor recurrence following selective bladder preservation in muscle-invasive bladder cancer patients. The 107th annual meeting of the American Urological Association, San Diego, USA, 2013/5/6

  11. Ishioka J, Saito K, Matsuoka Y, Numao N, Koga F, Masuda H, Fujii Y, Sakai Y, Okuno T, Arisawa C, Kamata S, Nagahama K, Yonese J, Noro A, Tsujii T, Morimoto S, Kitahara S, Goto S, Higashi Y, Kihara K. Risk stratification for bladder recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma. The 107th annual meeting of the American Urological Association, San Diego, USA, 2013/5/6

  12. Ishioka J, Masuda H, Matsuoka Y, Numao N, Koga F, Saito K, Fujii Y, Sakai Y, Okuno T, Arisawa C, Kamata S, Nagahama K, Yonese J, Noro A, Tsujii T, Morimoto S, Kitahara S, Goto S, Higashi Y, Kihara K. Bimodal pattern of the impact of body mass index on cancer-specific survival of upper urinary tract urothelial carcinoma patients: Multi-center study in a 1114-case Tokyo Metropolitan Database of Urologic Disease (TMDU) cohort. The 107th annual meeting of the American Urological Association, San Diego, USA, 2013/5/6

  13. Kijima T, Koga F, Fujii Y, Yoshida S, Tatokoro M, Kihara K. Radiosensitizing effect of zoledronic acid on renal cell carcinoma cells by downregulating STAT1. The 107th annual meeting of the American Urological Association, San Diego, USA, 2013/5/5

  14. Takeshita H, Masuda H, Saito K, Tanaka H, Komai Y, Sakai Y, Koga F, Yonese J, Noro A, Kawakami S, Yamada T, Fujii Y, Kihara K. Serum C-reactive protein as an indicator of survival after surgery for adrenal metastasis from multiple primary sites. The 107th annual meeting of the American Urological Association, San Diego, USA, 2013/5/4

  15. Waseda Y, Saito K, Ishioka J, Matsuoka Y, Numao N, Koga F, Masuda H, Fujii Y, Sakai Y, Okuno T, Arisawa C, Kamata S, Nagahama K, Yonese J, Noro A, Tsujii T, Morimoto S, Higashi Y, Fukui I, Kihara K. Presence of ureteral tumor was associated with poor prognosis in upper urinary tract urothelial carcinoma patients treated by nephroureterectomy: a multicenter database study of 1063 patients. The 107th annual meeting of the American Urological Association, San Diego, USA, 2013/5/6

原著

  1. Fukui N, Kohno Y, Ishioka JI, Fukuda H, Kageyama Y, Higashi Y. Treatment outcome of patients with extragonadal nonseminomatous germ cell tumors: the Saitama Cancer Center experience. Int J Clin Oncol. 18: 731-4, 2013. PubMed

  2. Yasuda Y, Saito K, Yuasa T, Kitsukawa S, Urakami S, Yamamoto S, Yonese J, Takahashi S, Fukui I. Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol. 18: 884-9, 2013.PubMed

  3. Yasuda Y, Fujii Y, Yuasa T, Kitsukawa S, Urakami S, Yamamoto S, Yonese J, Takahashi S, Fukui I. Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma. Int J Clin Oncol. 18: 877-83, 2013.PubMed

  4. Yasuda Y, Yuasa T, Yamamoto S, Urakami S, Ito M, Sukegawa G, Kitsukawa S, Yonese J, Fukui I. Evaluation of the RENAL Nephrometry Scoring System in Adopting Nephron-Sparing Surgery for cT1 Renal Cancer. Urol Int. 90: 179-83, 2013.PubMed

  5. Bae H, Yoshida S, Matsuoka Y, Nakajima H, Ito E, Tanaka H, Oya M, Nakayama T, Takeshita H, Kijima T, Ishioka J, Numao N, Koga F, Saito K, Akashi T, Fujii Y, Kihara K. Apparent diffusion coefficient value as a biomarker reflecting morphological and biological features of prostate cancer. Int Urol Nephrol. 2013 [in press]

  6. Fukui N, Kageyama Y, Higashi Y,Kihara K, Kizaka-Kondoh S, Hiraoka M, Shinojima T, Suzuki K, Oya M. Development of a novel interferon-α2b gene construct with a repetitive hypoxia-inducible factor binding site and its suppressive effects on human renal cell carcinoma cell lines in vitro. Int J Clin Oncol. 2013 [in press]

  7. Fukushima H, Masuda H, Yokoyama M, Tatokoro M, Yoshida S, Ishioka J, Matsuoka Y, Numao N, Koga F, Saito K, Fujii Y, Kihara K. iabetes mellitus with obesity is a predictor of recurrence in patients with non-metastatic renal cell carcinoma. Jpn J Clin Oncol. 43: 740-6, 2013.

  8. Ito M, Masuda H, Kawakami S, Fujii Y, Koga F, Saito K, Yamamoto S, Yonese J, Fukui I, Kihara K. mpact of lower urinary tract symptoms on prostate cancer risk among Japanese men with prostate-specific antigen ＜10 ng/mL and non-suspicious digital rectal examination. Int J Urol. 20: 1163-8, 2013.

  9. Kijima T, Koga F, Fujii Y, Yoshida S, Tatokoro M, Kihara K. Zoledronic acid sensitizes renal cell carcinoma cells to radiation by downregulating STAT1. PLoS One. 8: e64615, 2013.

  10. Kobayashi S*, Fujii Y* (*equally contributed), Koga F, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Masuda H, Kihara K. Impact of bladder neck involvement on progression in patients with primary non-muscle invasive bladder cancer: a prospective validation study. Urol Oncol, 2013 [in press]

  11. Kobayashi S, Koga F, Kajino K, Yoshida S, Ishii C, Tanaka H, Saito K, Masuda H, Fujii Y, Yamada T, Kihara K. Apparent diffusion coefficient value reflects invasive and proliferative potential of bladder cancer. J Mag Reso Imaging. 39:172-8, 2013.

  12. Koga F, Numao N, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K. Sensitivity to chemoradiation predicts development of metastasis in muscle-invasive bladder cancer patients. Urol Oncol. 7: 1270-5, 2013.

  13. Komai Y, Sakai Y, Gotohda N, Kobayashi T, Kawakami S, Saito N. A novel 3-dimensional analysis system for case-specific kidney anatomy and surgical simulation to facilitate clampless partial nephrectomy. Urology. 83: 500-6, 2013

  14. Komai Y, Numao N, Yoshida S, Matsuoka Y, Nakanishi Y, Ishii C, Koga F, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K. High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsy. J Urol. 190(3):867-73, 2013.

  15. Masuda H, Fukushima H, Kawakami S, Numao N, Fujii Y, Saito K, Koga F, Ishioka J, Yokoyama M, Kihara K. Impact of advanced age on biochemical recurrence after radical prostatectomy in Japanese men according to pathological stage. Jpn J Clin Oncol. 43:410-6, 2013.

  16. Masuda H, Kagawa M, Kawakami S, Numao N, Matsuoka Y, Yokoyama M, Yamamoto S, Yonese J, Fukui I, Kihara K. Body mass index influences prostate cancer risk at biopsy in Japanese men. Int J Urol. 20:701-7, 2013.

  17. Masuda H, Fukushima H, Kawakami S, Numao N, Fujii Y, Saito K, Koga F, Ishioka J, Yokoyama M, Kihara K. Impact of advanced age on biochemical recurrence after radical prostatectomy in Japanese men according to pathological stage. Jpn J Clin Oncol. 43:410-6, 2013.

  18. Matsubara N, Mukai H, Naito Y, Itoh K, Komai Y, Sakai Y. First experience of active surveillance before systemic target therapy in patients with metastatic renal cell carcinoma. Urology. 82(1): 118-23, 2013.

  19. Miyajima N, Tsutsumi S, Sourbier C, Beebe K, Mollapour M, Rivas C, Yoshida S, Trepel JB, Huang Y, Tatokoro M, Shinohara N, Nonomura K, Neckers L. The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models. Cancer Res. 73: 7022-33, 2013.

  20. Moriyama S, Takeshita H, Adachi A, Arai Y, Higuchi S, Tokairin T, Chiba K, Nakagawa K, Noro A. Simultaneous bilateral testicular metastases from renal clear cell carcinoma: A case report and review of the literature. Oncol lett. 2013 [in press]

  21. Naito S, Kinoshita H, Kondo T, Shinohara N, Kasahara T, Saito K, Takayama T, Masumori N, Takahashi W, Takahashi M, Terachi T, Ozono S, Naito S, Tomita Y. Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases: a multicenter study of 556 patients. Urology. 82:846-51, 2013.

  22. Numao N, Yoshida S, Komai Y, Ishii C, Kagawa M, Kijima T, Yokoyama M, Ishioka J, Matsuoka Y, Koga F, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K. Usefulness of pre-biopsy multiparametric magnetic resonance imaging and clinical variables to reduce initial prostate biopsy in men with suspected clinically localized prostate cancer. J Urol. 190:502-8, 2013.

  23. Takeshita H, Numao N, Kijima T, Yokoyama M, Ishioka J, Matsuoka Y, Koga F, Saito K, Masuda H, Kawakami S, Yamamoto S, Yonese J, Fujii Y, Kihara K. Diagnostic performance of initial transperineal 14-core prostate biopsy to detect significant cancer. Int Urol Nephrol. 45:645-52, 2013.

  24. Takeshita H, Chiba K, Kitayama S, Moriyama S, Omura R, Noro A. Triplet chemotherapy with paclitaxel, gemcitabine, and cisplatin as second-line therapy for advanced urothelial carcinoma. Modern chemotherapy. 2:1-7, 2013.

  25. Tatokoro M, Kihara K, Masuda H, Ito M, Yoshida S, Kijima T, Yokoyama M, Saito K, Koga F, Kawakami S, Fujii Y. Successful reduction of hospital-acquired methicillin-resistant Staphylococcus aureus in a urology ward: a 10-year study. BMC Urol. 18(13): 35，2013.

  26. Yamamoto S, Fujii Y, Masuda H, Urakami S, Saito K, Kozuka T, Oguchi M, Fukui I, Yonese J. Longitudinal change in health-related quality of life after intensity-modulated radiation monotherapy for clinically localized prostate cancer. Qual Life Res. 2013 [in press]

  27. Yamamoto S, Kawakami S, Yonese J, Fujii Y, Urakami S, Kitsukawa S, Masuda H, Ishikawa Y, Kozuka T, Oguchi M, Kohno A, Fukui I. Long-term oncological outcome in men with T3 prostate cancer: radical prostatectomy versus external-beam radiation therapy at a single institution. Int J Clin Oncol. 2013 [in press]

  28. Yoshida S, Tsutsumi S, Muhlebach G, Sourbier C, Lee MJ, Lee S, Vartholomaiou E, Tatokoro M, Beebe K, Miyajima N, Mohney RP, Chen Y, Hasumi H, Xu W, Fukushima H, Nakamura K, Koga F, Kihara K, Trepel J, Picard D, Neckers L. Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis. Proc Natl Acad Sci U S A. 10:E1604-12, 2013.

  29. Yoshida S, Kobayashi S, Koga F, Ishioka J, Ishii C, Tanaka H, Nakanishi Y, Matsuoka Y, Numao N, Saito K, Masuda H, Fujii Y, Kihara K. Apparent diffusion coefficient as a prognostic biomarker of upper urinary tract cancer: a preliminary report. Eur Radiol. 23:2206-14, 2013.

  30. Yuasa T, Kitsukawa S, Sukegawa G, Yamamoto S, Kudo K, Miyazawa K, Kozuka T,Harada S, Yonese J. Early onset recall pneumonitis during targeted therapy with sunitinib. BMC Cancer. 2013 Jan 2; 13: 3.

  31. 石岡淳一郎、齋藤一隆、古賀文隆、藤井靖久、有澤千鶴、鎌田成芳、森本信二、 辻井俊彦、 北原聡史、後藤修一、東 四雄、福井　巌、木原和徳． 上部尿路上皮癌術後の膀胱内再発予測モデル． 日本泌尿器科学会雑誌. 104(2):342, 2013.

  32. 影山幸雄、河野友亮、福井直隆、東　四雄、田中洋一． 膀胱上皮内癌に対する抗がん剤維持膀胱内注入療法の試み． 埼玉県医学会雑誌. 48(1):325-8, 2013.

  33. Yokoyama M, Masuda H, Kihara K. Negative pressure wound therapy for surgical site infection associated with artificial urinary sphincter implantation. Int J Urol. 20: 1049-50, 2013.PubMed

  34. 北山沙知、入山哲次、高沢亮治、伊藤将也、木島敏樹、中西泰一、小林秀一郎、横山みなと、沼尾昇、兵地信彦、川上 理、 辻井俊彦． 立体14カ所生検所見に基づく前立腺癌積極的監視療法における再生検の意義． 泌尿器外科. 26:1249-52, 2013.

  35. 河野友亮、福井直隆、影山幸雄、東　四雄． Stage I 精巣癌のフォローアップにおける腫瘍マーカー測定の有用性：3症例の検討． 西日泌尿. 75:27－30, 2013.

  36. 河野友亮、福井直隆、影山幸雄、東　四雄． エンドトキシン吸着療法により救命しえたESBL産生菌による経直腸針生検後敗血症の一例． 泌尿紀要. 59:593-6, 2013.

  37. 河野友亮、影山幸雄、福井直隆、東 四雄、田中洋一． 前立腺全摘後に発症した上部尿路上皮癌の３例． 埼玉県医学会雑誌. 48(1):329-31, 2013.

  38. 古賀文隆、木原和徳、松岡　陽、沼尾　昇、齋藤一隆、増田　均. ミニマム創内視鏡下膀胱部分切除／骨盤リンパ節郭清を主軸とする浸潤性膀胱癌に対する新しい膀胱温存療法． Audio-Visual Journal of JUA. 19:19-10, 2013.

  39. 高沢亮治、北山沙知、辻井俊彦． 軟性腎盂尿管ビデオスコープを用いた特発性腎出血の診断． Audio-Visual Journal of JUA． 19(4):2013.

  40. 沼尾　昇、吉田宗一郎、横山みなと、石岡淳一郎、松岡　陽、古賀文隆、齋藤一隆、藤井靖久、伴　大輔、小林宏寿、小嶋一幸、木原和徳． ミニマム創内視鏡下手術の教育システムの実践． 泌尿器外科. 26(4):516-7, 2013.

  41. 福井直隆、河野友亮、小川一栄． 画像診断による発見が困難であった後腹膜脂肪肉腫． 臨床泌尿器科. 67:618-22,2013.

  42. 福井直隆、河野友亮、影山幸雄、東四雄、田中洋一. 当科における腎癌脳転移症例の検討． 埼玉県医学会雑誌. 48:332-4, 2013.

  43. 森山真吾、吉田宗一郎、竹下英毅、倉田盛人、岡田洋平、斎藤一隆、古賀文隆、増田 均、藤井靖久, 川上 理, 木原和徳． 拡散強調MR画像にて高信号を呈した膀胱炎症性病変の1例．組織学的所見との比較による考察． 日本泌尿器科学会雑誌. 104:545-8, 2013.

総説

  1. Koga F, Yokoyama M, Fukushima H. Small cell carcinoma of the urinary bladder: A contemporary review with a special focus on bladder-sparing treatments. Expert Rev Anticancer Ther. 13:1269-79, 2013.

  2. Saito K, Kihara K. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes. Int J Urol. 20:161-71, 2013.

  3. 影山幸雄． 陰茎保存、陰茎切除の実際：陰茎癌の診断と治療． 泌尿器外科. 26(6):927-33, 2013．

  4. 木原和徳． ミニマム創内視鏡下手術の最先端型：ガスレス・シングルポート・ロボサージャン手術． 日本ミニマム創内視鏡下外科学会雑誌. 5:1113-8, 2013．

  5. 石岡淳一郎、吉田宗一郎、横山みなと、松岡　陽、沼尾　昇、斎藤一隆、古賀文隆、増田　均、藤井靖久、木原和徳． ミニマム創内視鏡下手術に役立つ器具の紹介． 日本ミニマム創泌尿器内視鏡外科学会雑誌. 4(2):56-7,2012.

  6. 古賀文隆、松岡　陽、沼尾　昇、齋藤一隆、増田　均、藤井靖久、木原和徳. 3D-HMD・ガスレス・シングルポート膀胱部分切除／膀胱全摘除． 日本ミニマム創泌尿器内視鏡外科学会雑誌. 5:93-6, 2013．

  7. 齋藤一隆、竹下英毅、木島敏樹、吉田宗一郎、横山みなと、石岡淳一郎、松岡　陽、沼尾　昇、古賀文隆、増田　均、藤井靖久、木原和徳. 3D-HMD・ガスレス・シングルポート腎尿管全摘除／根治的腎摘除． 日本ミニマム創内視鏡下外科学会雑誌. 5:87-91, 2013．

  8. 齋藤一隆． アップデートシリーズ　腎がんの治療　予後因子． 泌尿器ケア. 18:83-6, 2013．

  9. 齋藤一隆、木原和徳． 特集１前立腺癌マーカー：CRPによるフォロー，予後の推定． 臨床検査. 57:1464-8, 2013．

  10. 齋藤典男、酒井康之、駒井好信、伊藤雅昭、小林昭広、西澤雄介、杉藤正典． 局所高度進行直腸癌に対する外科治療—隣接臓器合併切除を伴う拡大切除． 外科. 75:250-6, 2013．

  11. 藤井靖久、松岡 陽、沼尾 昇、齋藤一隆、古賀文隆、増田 均、木原和徳． 3D-HMD・ガスレス・シングルポート・前立腺全摘除． 日本ミニマム創内視鏡下外科学会雑誌. 5:21-5, 2013．

  12. 藤井靖久、松岡　陽、沼尾　昇、齋藤一隆、古賀文隆、増田　均、木原和徳． 3D-HMD・ガスレス・シングルポート・無阻血腎部分切除． 日本ミニマム創内視鏡下外科学会雑誌. 5:159-64, 2013．

  13. 藤井靖久、木原和徳． 陰茎腫瘍: 後期研修医がおさえておきたい泌尿器疾患Top30． 泌尿器外科. 26特別号:146-51, 2013．

  14. 藤井靖久． 前立腺全摘除術後の鼠径ヘルニア防止法について教えてください． Prostate Cancer　Frone Line. 2:16-9, 2013．

  15. 藤井靖久． 免疫療法（サイトカイン療法）．アップデートシリーズ　腎がんの治療． 泌尿器ケア.　 18:72－4, 2013．

  16. 藤井靖久、横山みなと、木原和徳． 腎部分切除後の腎機能． 泌尿器外科. 26:1801-6, 2013．

  17. 増田　均. 前立腺全摘除後の合併症―予防と対処：尿失禁：軽症～中等度―男性スリング手術． 臨床泌尿器科.　 67:217-22, 2013．

  18. 増田　均、平川菜穂美． 膀胱癌． プロフェッショナルがんナーシング. 3:48-53, 2013．

  19. 増田　均． 人工尿道括約筋―手術の実際とコツ． Urology Today. 20:32-6, 2013．

  20. 増田　均． 前立腺癌　第36回　尿失禁に対する男性用スリング手術．　 排尿障害プラクティス. 21(3): 53-60, 2013．

  21. 松岡　陽、沼尾　昇、木原和徳． 前立腺生検の手法：MRI所見の活用． 泌尿器外科. 26:15-9, 2013．

  22. 松岡　陽、木原和徳． 3D-HMDを用いた内視鏡下手術における超音波装置活用． 新医療. 40:97-101, 2013．

  23. 湯浅　健、齋藤一隆、藤井靖久． 特集　分子標的薬時代5年目を迎えた進行腎癌の治療戦略の現状と展望：効果，副作用，予後に関するバイオマーカー． 臨床泌尿器科. 67:75-81, 2013.

  24. 米瀬淳二． 【治療に伴う看護特集　がん患者の術後ドレーン・チューブ管理】 前立腺がん手術． プロフェッショナルがんナーシング　 3:369-71,2013．

  25. 横山みなと, 藤井靖久, 吉田宗一郎, 石岡淳一郎, 沼尾　昇, 松岡　陽, 古賀文隆, 齋藤一隆, 増田　均, 木原和徳． ミニマム創内視鏡下（ガスレス・シングルポート）無阻血腎部分切除後の腎機能の検討：Tumor complexityは術後腎機能に影響を与えるか？ 日本ミニマム創内視鏡下外科学会雑誌. 5: 119-23, 2013.

  26. 米瀬淳二． 【患者さんへの説明にそのまま使える!泌尿器がんのすべて】　(7章)陰茎がん. 泌尿器ケア 夏季増刊.　294-305,2013．

著書

  1. 石岡淳一郎、増田　均、木原和徳. 病棟レジデント、病棟医のための高齢患者診療マニュアル、25章　排尿障害・尿失禁. メディカル・サイエンス・インターナショナル. 214-7, 2013.

  2. 影山幸雄、石岡淳一郎、東　四雄、木原和徳． 膀胱癌、浸潤癌（温存療法）．腎癌・膀胱癌 木原和徳編 最新医学社. 156-63, 2013．

  3. 影山幸雄． 解剖を実践に生かす―図解前立腺全摘術． 医学書院. 2013

  4. 木原和徳. 前立腺肥大症（膀胱下（尿道）閉鎖を含む）．今日の治療指針　山口　徹、北原光夫編集 医学書院. 2013.

  5. 沼尾　昇、木原和徳． 腎疝痛. 腎と透析74 2013臨時増刊号: 腎疾患治療薬マニュアル2013-2014 東京医学社. p116-8, 2013.

  6. 藤井靖久． XII泌尿器の癌 Q429腎臓の働きについて教えてください． Q430腎癌の危険因子は何ですか？ Q431腎癌の腎外症状(paraneoplastic syndrome)とは何ですか？ Q432腎癌の診断に有用な検査は何ですか？　新癌についての質問に答える．小川道雄　監修　へるす出版 へるす出版. 438-41, 2013．

  7. 藤井靖久、木原和徳． ミニマム創内視鏡下手術．新版　泌尿器科周術期管理のすべて．荒井陽一、松田公志、高橋　悟　編 メジカルビュー社 . 210-20, 2013．

  8. 松岡　陽, 木原和徳． 標準臨床検査学 臨床医学総論．腎・尿路・男性生殖器疾患. 医学書院. 124:132-6, 2013.

研究会主催

  1. 第6回日本ミニマム創泌尿器内視鏡外科学会、東京、2013年12月21, 22日.

研究助成

  1. 古賀文隆．膀胱癌の転移／治療耐性における p63 蛋白の役割．文部科学省　科学研究費補助金：基盤(C) 23501266．

  2. 吉田宗一郎．ミトコンドリア局在型熱ショックタンパク質90の機能調節による癌治療戦略．日本学術振興会 科学研究費, 若手研究(B), 2013年.

  3. 吉田宗一郎. 腎細胞癌および膀胱癌の転移能獲得におけるミトコンドリア局在型熱ショックタンパク質90 (TRAP1)の役割解明. 鈴木泌尿器医学振興財団　研究助成, 2013年

  4. 駒井好信．進行性悪性腫瘍を原因とする尿管閉塞に対する尿管ステント留置の有効性の検証．タカイ医科工業グラント，2013 年．